One-Year Effectiveness and Safety of Dupilumab Treatment for Moderate-to-Severe Atopic Dermatitis in Korean Patients: A Real-World Retrospective Analysis

Dupilumab was the first biological drug to be approved for adult patients with moderate-to-severe atopic dermatitis (AD), and its use is growing exponentially worldwide. Though its therapeutic efficacy and favorable safety profile have been demonstrated, data on real-world long-term experience with...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Hanjae, Kim, Bo Ri, Kim, Kyu Han, Lee, Dong Hun, Na, Jung Im
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease 2021
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724830/
https://www.ncbi.nlm.nih.gov/pubmed/34983111
http://dx.doi.org/10.4168/aair.2022.14.1.117

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724830/
https://www.ncbi.nlm.nih.gov/pubmed/34983111
http://dx.doi.org/10.4168/aair.2022.14.1.117

Ejemplares similares